Elanco Animal Health has partnered with South Dakota-based Medgene to commercialize a highly pathogenic avian influenza (HPAI) vaccine for dairy cattle.
Medgene’s vaccine has met USDA platform technology guidelines and is nearing conditional license approval. The ongoing HPAI outbreak, now in its fourth year, has spread to nearly 1,000 dairy herds.
“As egg prices soar and milk production wanes in infected dairies, the need for new solutions to curb disease spread is evident,” said Jeff Simmons, president and CEO of Elanco Animal Health. “Elanco is pleased to partner with Medgene to bring customers options to fight this devastating disease and believes this product will become part of a routine vaccination protocol for the U.S. dairy industry.”
